Investors sold shares of Celgene Co. (NASDAQ:CELG) on strength during trading hours on Thursday. $60.18 million flowed into the stock on the tick-up and $109.68 million flowed out of the stock on the tick-down, for a money net flow of $49.50 million out of the stock. Of all equities tracked, Celgene had the 20th highest net out-flow for the day. Celgene traded up $1.03 for the day and closed at $89.74
Several equities analysts recently commented on CELG shares. Leerink Swann reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Celgene in a research report on Wednesday, December 13th. Oppenheimer set a $166.00 price objective on shares of Celgene and gave the company a “buy” rating in a research report on Thursday, December 14th. Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective for the company. in a research report on Monday, December 18th. Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a research report on Thursday, December 21st. Finally, Stifel Nicolaus reduced their price target on shares of Celgene from $149.00 to $130.00 and set a “buy” rating for the company in a research report on Friday, December 22nd. Four analysts have rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $127.68.
The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29. The firm has a market cap of $67,274.59, a price-to-earnings ratio of 13.12, a P/E/G ratio of 0.60 and a beta of 1.49.
Celgene declared that its board has authorized a stock repurchase plan on Wednesday, February 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.
In related news, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $95.99, for a total value of $887,907.50. Following the sale, the director now owns 94,801 shares of the company’s stock, valued at approximately $9,099,947.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark J. Alles purchased 3,260 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the purchase, the insider now directly owns 178,904 shares in the company, valued at approximately $16,441,277.60. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 41,120 shares of company stock valued at $3,879,509. Insiders own 0.95% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Ark Investment Management LLC boosted its stake in Celgene by 78.7% during the 2nd quarter. Ark Investment Management LLC now owns 1,599 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 704 shares during the last quarter. Scotia Capital Inc. boosted its stake in Celgene by 21.0% during the 2nd quarter. Scotia Capital Inc. now owns 69,457 shares of the biopharmaceutical company’s stock worth $9,020,000 after purchasing an additional 12,058 shares during the last quarter. Linscomb & Williams Inc. boosted its stake in Celgene by 1.0% during the 2nd quarter. Linscomb & Williams Inc. now owns 3,813 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 36 shares during the last quarter. Chiron Investment Management LLC boosted its stake in Celgene by 38.4% during the 2nd quarter. Chiron Investment Management LLC now owns 131,800 shares of the biopharmaceutical company’s stock worth $17,117,000 after purchasing an additional 36,600 shares during the last quarter. Finally, Cypress Capital Group boosted its stake in Celgene by 12.6% during the 2nd quarter. Cypress Capital Group now owns 39,742 shares of the biopharmaceutical company’s stock worth $5,162,000 after purchasing an additional 4,450 shares during the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://dakotafinancialnews.com/2018/04/13/investors-sell-celgene-celg-on-strength-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.